AT-406 (SM-406): Orally Bioavailable IAP Inhibitor for Apoptosis Pathway Activation

Executive Summary. AT-406 (SM-406) is a small-molecule, orally bioavailable inhibitor of apoptosis proteins (IAPs), including XIAP, cIAP1, and cIAP2, exhibiting nanomolar binding affinity (Ki: 66.4 nM, 1.9 nM, 5.1 nM, respectively) and robust induction of apoptosis in cancer cells [APExBIO]. It disrupts IAP-caspase complexes, enabling caspase-3, -7, and -9 activation and programmed cell death (Yang et al., 2024). AT-406 demonstrates in vitro IC₅₀ values of 0.05–0.5 μg/mL in ovarian cancer cells and sensitizes them to carboplatin chemotherapy. In vivo, it significantly inhibits tumor growth and extends survival in mouse xenograft models of ovarian and breast cancer. The compound is well-tolerated clinically at doses up to 900 mg orally, with favorable pharmacokinetics.

Biological Rationale

Inhibitor of apoptosis proteins (IAPs) are a conserved protein family that regulate caspase activity and inhibit programmed cell death (apoptosis). Key IAPs such as X-linked inhibitor of apoptosis protein (XIAP), cellular IAP1 (cIAP1), and cIAP2 bind and suppress caspase-3, -7, and -9, acting as cellular gatekeepers for apoptosis (Yang et al., 2024). Overexpression of IAPs is frequently observed in various cancer types and is associated with tumor progression, chemoresistance, and poor prognosis. Targeting IAPs reactivates apoptotic signaling in cancer cells, making them susceptible to cell death and enhancing the efficacy of chemotherapeutics. Small-molecule IAP inhibitors, such as AT-406, directly antagonize IAP-caspase interactions, representing a strategic approach in translational oncology research [AT-406: Redefining IAP Inhibition].

Mechanism of Action of AT-406 (SM-406)

AT-406 is a potent, orally bioavailable small molecule that binds the baculoviral IAP repeat (BIR) domains of XIAP, cIAP1, and cIAP2, disrupting their interaction with caspase-3, -7, and -9 [APExBIO]. The compound exhibits Ki values of 66.4 nM for XIAP, 1.9 nM for cIAP1, and 5.1 nM for cIAP2, indicating high affinity. Upon binding, AT-406 induces rapid proteasomal degradation of cIAP1, leading to downstream activation of caspase cascades and apoptotic cell death. In the context of death receptor (DR) signaling, AT-406 facilitates the assembly and activation of death-inducing signaling complexes (DISCs), enabling efficient procaspase-8 and caspase-3 activation (Yang et al., 2024). These effects culminate in the reversal of apoptosis resistance in tumor cells. For a detailed workflow on integrating AT-406 into apoptosis pathway studies, see AT-406 (SM-406): IAP Inhibitor Workflows for Cancer Research (this article extends prior workflow descriptions by providing explicit concentration and timing parameters).

Evidence & Benchmarks

• AT-406 antagonizes XIAP, cIAP1, and cIAP2 with Ki values of 66.4 nM, 1.9 nM, and 5.1 nM, respectively (see Table 1, APExBIO).
• In vitro, AT-406 demonstrates IC₅₀ values of 0.05–0.5 μg/mL in human ovarian cancer cell lines under standard cell culture conditions (RPMI-1640, 37°C, 5% CO₂, 24 h) (APExBIO).
• AT-406 sensitizes ovarian cancer cells to carboplatin, significantly lowering the IC₅₀ of carboplatin in co-treatment experiments (see data summary, AT-406: Redefining IAP Inhibition).
• In vivo, oral AT-406 inhibits tumor progression and prolongs survival in mouse xenograft models of ovarian and breast cancer (20 mg/kg, p.o., daily for 14 days) (AT-406: Next-Gen IAP Inhibitor).
• AT-406 is well tolerated in patients at oral doses up to 900 mg, with no dose-limiting toxicity observed in early clinical trials (Phase I, solid tumors; APExBIO).
• Structural studies of DR/caspase complexes validate the mechanistic rationale for IAP inhibition and apoptosis pathway reactivation (Yang et al., 2024).

Applications, Limits & Misconceptions

AT-406 is primarily used for:

• Inducing apoptosis in cancer cell lines (ovarian, breast, and others) via direct IAP inhibition.
• Sensitizing resistant tumor cells to chemotherapeutics (e.g., carboplatin).
• Modeling caspase activation and dissecting apoptosis pathways in vitro and in vivo.
• Preclinical studies of IAP-targeted therapies and translational oncology workflows.

For in-depth mechanistic perspectives, this article extends the foundational discussion in Expanding the Apoptosis Frontier by explicitly mapping AT-406's benchmarks to structure-guided apoptosis pathway models.

Common Pitfalls or Misconceptions

• AT-406 is not effective in cell lines with complete loss of caspase-3, -7, or -9 function, as apoptosis activation is downstream of these effectors.
• The compound does not directly induce necroptosis or autophagy; its primary action is caspase-mediated apoptosis.
• AT-406 is insoluble in water and must be prepared in DMSO or ethanol for in vitro or in vivo use (≥27.65 mg/mL solubility).
• Extended storage of AT-406 solutions at room temperature can cause degradation; short-term use and -20°C storage are recommended.
• The compound’s efficacy is reduced in tumors with alternative apoptosis resistance mechanisms unrelated to IAP overexpression.

Workflow Integration & Parameters

AT-406 (A3019) from APExBIO is supplied as a solid (MW 561.71), recommended for storage at -20°C. For typical in vitro workflows, prepare stock solutions in DMSO or ethanol (≥27.65 mg/mL). Treat cultured cancer cells at 0.1–3 μM for 24 hours to analyze apoptosis and caspase activation by flow cytometry or Western blot. For in vivo tumor models, oral gavage at 10–20 mg/kg daily for 1–2 weeks is standard. Sensitization assays with carboplatin should use co-treatment conditions, monitoring cell viability and caspase cleavage. Refer to AT-406 (SM-406): IAP Inhibitor Workflows for Cancer Research for troubleshooting and optimization strategies. This article provides explicit parameterization and highlights storage/handling issues not addressed in AT-406 (SM-406): IAP Inhibitor Empowering Advanced Apoptosis Research (which focuses on translational impact and resistance models).

Conclusion & Outlook

AT-406 (SM-406) is a validated, potent IAP inhibitor enabling precise modulation of apoptosis pathways in cancer research. Its robust in vitro and in vivo efficacy, oral bioavailability, and clinical tolerability profile position it as a benchmark tool for translational apoptosis studies and preclinical therapy development. For more details and ordering information, refer to the AT-406 (SM-406) product page at APExBIO. Ongoing studies will further define its clinical applications and combination therapy potential.